BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) ( www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that the Company's line of hyperthermia products was featured at the recent 2012 International Congress of Hyperthermic Oncology (ICHO) Conference, which was held as a joint conference with the Japanese Congress of Thermal Medicine in Kyoto, Japan. The conference included symposium and presentations by pre-eminent researchers of the latest research on hyperthermia, and BSD's equipment was featured in many of these presentations. The clinical studies demonstrated a significantly improved outcome from the addition of hyperthermia, delivered using BSD's equipment, to radiotherapy and/or chemotherapy for the treatment of a large variety of tumors, including sarcoma, prostate cancer, pancreatic cancer, head and neck malignancies, recurrent breast cancer, cervical cancer, and pelvic tumors. One of the many presentations included a review of the current status of clinical hyperthermia in China that focused on the BSD-2000 Hyperthermia System.
“BSD met with key hyperthermia researchers and clinicians during the conference. We are pleased with the level of interest in hyperthermia shown by both the U.S. and the international medical community and distributors,” stated Harold R. Wolcott, President of BSD Medical. "Attendance at this international conference allowed the Company to build worldwide awareness of BSD's hyperthermia products."
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market and well established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.